



The Role of DPO-1 and XE991-Sensitive Potassium Channels in Perivascular Adipose Tissue-Mediated Regulation of Vascular Tone

Dmitry Tsvetkov^{1†}, Jean-Yves Tano^{1†}, Mario Kassmann^{1†}, Ning Wang¹, Rudolf Schubert² and Maik Gollasch^{1,3*}

¹ Experimental and Clinical Research Center, A Joint Cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association of German Research Centres, Berlin, Germany, ² Research Division Cardiovascular Physiology, Centre for Biomedicine and Medical Technology Mannheim, Medical Faculty Mannheim of the University Heidelberg, Mannheim, Germany, ³ Medical Clinic for Nephrology and Internal Intensive Care, Charité University Medicine, Berlin, Germany

OPEN ACCESS

Edited by:

Iain A. Greenwood,
St George's, University of London, UK

Reviewed by:

Sergey V. Smirnov,
University of Bath, UK
Sarah B. Withers,
University of Manchester, UK
Thomas Andrew Jepps,
University of Copenhagen, Denmark

*Correspondence:

Maik Gollasch
maik.gollasch@charite.de

[†]These authors have contributed
equally to this work.

Specialty section:

This article was submitted to
Vascular Physiology,
a section of the journal
Frontiers in Physiology

Received: 21 April 2016

Accepted: 20 July 2016

Published: 04 August 2016

Citation:

Tsvetkov D, Tano J-Y, Kassmann M, Wang N, Schubert R and Gollasch M (2016) The Role of DPO-1 and XE991-Sensitive Potassium Channels in Perivascular Adipose Tissue-Mediated Regulation of Vascular Tone. *Front. Physiol.* 7:335. doi: 10.3389/fphys.2016.00335

The anti-contractile effect of perivascular adipose tissue (PVAT) is an important mechanism in the modulation of vascular tone in peripheral arteries. Recent evidence has implicated the XE991-sensitive voltage-gated K_V (KCNQ) channels in the regulation of arterial tone by PVAT. However, until now the *in vivo* pharmacology of the involved vascular K_V channels with regard to XE991 remains undetermined, since XE991 effects may involve Ca^{2+} activated BK_{Ca} channels and/or voltage-dependent $K_V1.5$ channels sensitive to diphenyl phosphine oxide-1 (DPO-1). In this study, we tested whether $K_V1.5$ channels are involved in the control of mesenteric arterial tone and its regulation by PVAT. Our study was also aimed at extending our current knowledge on the *in situ* vascular pharmacology of DPO-1 and XE991 regarding $K_V1.5$ and BK_{Ca} channels, in helping to identify the nature of K^+ channels that could contribute to PVAT-mediated relaxation. XE991 at 30 μ M reduced the anti-contractile response of PVAT, but had no effects on vasoconstriction induced by phenylephrine (PE) in the absence of PVAT. Similar effects were observed for XE991 at 0.3 μ M, which is known to almost completely inhibit mesenteric artery VSMC K_V currents. 30 μ M XE991 did not affect BK_{Ca} currents in VSMCs. *Kcna5*^{-/-} arteries and wild-type arteries incubated with 1 μ M DPO-1 showed normal vasocontractions in response to PE in the presence and absence of PVAT. K_V current density and inhibition by 30 μ M XE991 were normal in mesenteric artery VSMCs isolated from *Kcna5*^{-/-} mice. We conclude that K_V channels are involved in the control of arterial vascular tone by PVAT. These channels are present in VSMCs and very potently inhibited by the KCNQ channel blocker XE991. BK_{Ca} channels and/or DPO-1 sensitive $K_V1.5$ channels in VSMCs are not the downstream mediators of the XE991 effects on PVAT-dependent arterial vasorelaxation. Further studies will need to be undertaken to examine the role of other K_V channels in the phenomenon.

Keywords: XE991, KCNQ channels, $K_V1.5$ channels, adipocyte-derived relaxing factor (ADRF), perivascular adipose tissue (PVAT), BK channels

INTRODUCTION

Over the past decade, various potassium (K⁺) channels have been implicated as important players in the regulation of arterial vascular tone and its control by perivascular adipose tissue (PVAT). Opening of vascular smooth muscle cell (VSMC) K⁺ channels causes K⁺ efflux and membrane hyperpolarization, which leads to reduced Ca²⁺ influx through L-type Cav1.2 channels and consequently arterial relaxation (Nelson and Quayle, 1995). A variety of endogenous vasodilators, such as hypoxia, acidosis, as well as metabolites and autacoids (e.g., adenosine, prostacyclin) act as potent K⁺ channel openers to produce relaxation (Sobey, 2001; Tano and Gollasch, 2014). Noteworthy, many of these substances produce relaxation by opening maxi Ca²⁺ activated (BK_{Ca}) K⁺ channels in VSMCs (Bentzen et al., 2014). Only very few substances have been reported to relax vessels by opening arterial smooth muscle voltage-gated K_v channels (Tanaka et al., 2006; Park et al., 2015). Among them adenosine and atrial natriuretic peptide (ANP) act *via* activation of the KCNQ (K_v7) subfamily of K_v channels (Khanamiri et al., 2013; Stott et al., 2015).

Recent studies have demonstrated a paracrine role for PVAT to produce relaxation of arterial smooth muscle cells in a number of vascular beds (Lohn et al., 2002; Verlohren et al., 2004; Gao et al., 2005; Zavaritskaya et al., 2013). Certain adipokines, such as adiponectin (Weston et al., 2013), angiotensin-1 to 7 (Lee R. M. K. W. et al., 2011), methyl palmitate (Lee Y.-C. et al., 2011), and notably H₂S (Schleifenbaum et al., 2010) were recently proposed as potential perivascular-derived relaxing factors (PVRFs), which could mediate the anti-contractile properties of PVAT. The paracrine effects of PVAT involve the opening of K⁺ channels, however, the identity of the K⁺ channel subtype(s) involved is still a matter of debate (Tano et al., 2014).

Voltage-gated K_v channels of the KCNQ (K_v7) family have been proposed to play an important role in PVAT control of arterial tone. This conclusion is based on observations demonstrating that the anti-contractile effects of PVAT are inhibited by the pan KCNQ channel blocker XE991 at 30 μM or the pan K_v channel blocker 4-aminopyridine (2 mmol/L; Fésüs et al., 2007; Schleifenbaum et al., 2010; Lee Y.-C. et al., 2011; Zavaritskaya et al., 2013). XE991 is a widely used pan K_v7 channel blocker, which inhibits K_v7.1 homomeric or K_v7.1/KCNE channels (IC₅₀ of ~0.8 μM and 11.1 μM, respectively; Wang et al., 2000), KCNQ2/3 channels (EC₅₀ ~1 μM; Wang et al., 1998), KCNQ4 (EC₅₀ ~5.5 μM; Søgaard et al., 2001), and KCNQ5 (EC₅₀ ~65 μM; Schroeder et al., 2000). Noteworthy, XE991 can also inhibit other K_v channels, such as ERG (K_v11; EC₅₀ ~110 μM) (Elmedyeb et al., 2007) and K_v1.2/1.5, K_v2.1/K_v9.3 channels (~30% inhibition at 10 μM) in heterologous expression systems (Zhong et al., 2010).

However, it is unknown whether XE991 is indeed specific for vascular K_v channels *in situ*, and does not inhibit native BK_{Ca} channels. This is particularly relevant since BK_{Ca} channels have been proposed to play a role in PVAT control of arterial tone in other studies (Lynch et al., 2013; Weston et al., 2013), although studies using BK_{Ca} deficient mice gave opposing results (Fésüs et al., 2007). A recent study showed that K_v channels in

VSMCs of mouse mesenteric arteries are very sensitive to XE991 (EC₅₀ ~60 nM), suggesting that these channels may contribute to PVAT control of arterial tone (Schleifenbaum et al., 2010, 2014). A very recent study suggested that diphenyl phosphine oxide-1 (DPO-1) sensitive K_v1.5 channels could contribute to the K_v current in VSMC (Fancher et al., 2015).

Therefore, we tested whether K_v1.5 channels are involved in the control of arterial tone and its regulation by PVAT or not. Our study is also aimed at extending our current knowledge on the *in situ* vascular pharmacology of DPO-1 and XE991 regarding K_v1.5 and BK_{Ca} channels, in helping to identify the nature of K⁺ channels that could contribute to PVAT-mediated relaxation.

METHODS

Mouse Model

We used *Kcna5*^{-/-} mice as previously described (Pannasch et al., 2006). The mouse model was evaluated by RT-qPCR (Figure S1). Either litter- or age-matched (10–14 weeks old) male wild-type (129S6 background, previously known as 129SvEv-Ta) mice were used as controls. 250–300 g male Sprague Dawley rats were obtained from Charles River, Germany, Berlin. All experimental procedures were performed in accordance with the German legislation on protection of animals. Animal care followed American Physiological Society guidelines, and local authorities (Landesamt für Gesundheit und Soziales Berlin, LAGeSo) approved all protocols. Mice were housed in individually ventilated cages under standardized conditions with an artificial 12-h dark–light cycle with free access to water and food.

Wire Myography

First order mesenteric arteries were removed immediately after killing the mice or rats under inhalation anesthesia with isoflurane by cervical dislocation, quickly transferred to cold (4°C), oxygenated (95% O₂/5% CO₂) physiological salt solution (PSS) containing (in mmol/L) 119 NaCl, 4.7 KCl, 1.2 KH₂PO₄, 25 NaHCO₃, 1.2 MgSO₄, 11.1 glucose, 1.6 CaCl₂, and dissected into 2 mm rings whereby perivascular fat and connective tissue were either intact [(+) PVAT or removed (-) PVAT] without damaging the adventitia. Each ring was positioned on two stainless steel wires (diameter 0.0394 mm) in a 5-ml organ bath of a Mulvany Small Vessel Myograph (DMT 610 M; Danish Myo Technology, Denmark). The organ bath was filled with PSS. The bath solution was continuously oxygenated with a gas mixture of 95% O₂ and 5% CO₂, and kept at 37°C (pH 7.4) (Verlohren et al., 2004; Fésüs et al., 2007). The mesenteric rings were placed under a tension equivalent to that generated at 0.9 times the diameter of the vessel at 100 mm Hg by stepwise distending the vessel using LabChart DMT Normalization module. This normalization procedure was performed to obtain the passive diameter of the vessel at 100 mm Hg (Fésüs et al., 2007). The software Chart5 (AD Instruments Ltd. Spechbach, Germany) was used for data acquisition and display. After 60 min equilibration arteries were pre-contracted either with isotonic external 60 mmol/L KCl until a stable resting tension was acquired. The composition of 60 mM KCl (in mmol/L) was 63.7 NaCl, 60 KCl, 1.2 KH₂PO₄, 25 NaHCO₃, 1.2 Mg₂SO₄, 11.1 glucose, and 1.6 CaCl₂. Drugs were

added to the bath solution if not indicated otherwise. Tension is expressed as a percentage of the steady-state tension (100%) obtained with isotonic external 60 mM KCl.

Isolation of Arterial VSMCs

VSMCs from mesenteric arteries were isolated as described (Gollasch et al., 1998; Plüger et al., 2000). Briefly, the arteries were isolated and quickly transferred to cold (4°C) oxygenated (95% O₂-5% CO₂) PSS. The arteries were cleaned, cut into pieces, and placed into a Ca²⁺-free Hank's solution (in mmol/L): 55 NaCl, 80 sodium glutamate, 5.6 KCl, 2 MgCl₂, 1 mg/ml bovine serum albumin (BSA, Sigma, Taufkirchen), 10 glucose, and 10 HEPES (pH 7.4 with NaOH) containing 0.5 mg/ml papain (Sigma) and 1.0 mg/ml DTT for 50 min at 37°C. The segments then were placed in Hank's solution containing 1 mg/ml collagenase (Sigma, type F and H, ratio 30 and 70%, respectively) and 0.1 mmol/L CaCl₂ for 10 min at 37°C. Following several washes in Ca²⁺-free Hank's solution (containing 1 mg/ml BSA), single cells were dispersed from artery segments by gentle triturating. Cells were then stored in the same solution at 4°C.

Electrophysiology

Voltage dependent potassium (K_V) currents and BK_{Ca} currents were measured in the conventional whole-cell configuration of the patch-clamp technique at room temperature as previously described (Gollasch et al., 1996; Essin et al., 2007; Schleifenbaum et al., 2014). Patch pipettes (resistance 3–5 MΩ) for recording K_V currents were filled with a solution containing (in mmol/L): 130 KCl, 1 MgCl₂, 3 Na₂ATP, 0.1 Na₃GTP, 10 HEPES, and 5 EGTA (pH 7.2; Yeung and Greenwood, 2005). Patch pipettes for recording BK_{Ca} currents contained (in mmol/L): 130 KCl, 1 MgCl₂, 3 Na₂ATP, 0.1 Na₃GTP, 10 HEPES, 5 EGTA, and 4.3 CaCl₂ (estimated [Ca²⁺] free, 10⁻⁶ mol/L; pH 7.2). The external bath solution contained (in mmol/L): 126 NaCl, 5 KCl, 1 MgCl₂, 0.1 CaCl₂, 11 glucose and 10 HEPES (pH 7.2; Yeung and Greenwood, 2005). Holding potential was -60 mV. Whole cell currents were recorded using an Axopatch 200B amplifier (Axon Instruments/Molecular Devices, Sunnyvale, CA, USA) or an EPC 7 amplifier (List, Darmstadt, Germany) and digitized at 5 kHz, using a Digidata 1440A digitizer (Axon CNS, Molecular Devices), and pClamp software versions 10.1 and 10.2 (Schleifenbaum et al., 2014).

RT-qPCR

Total RNA was isolated from snap-frozen heart and aortae tissues with or without K_V1.5 by using the RNeasy RNA isolation kit (Qiagen, Hamburg, Germany) according to the manufacturer's instruction. Isolated RNA concentration was measured and RNA quality was tested by NanoDrop-1000 spectrophotometer (PiqLab, Erlangen, Germany). For the synthesis of cDNA, equivalent amounts of RNA (2 μg) were used and processed by a high capacity cDNA reverse transcription kit (Life Technologies GmbH, Darmstadt, Germany). Quantitative analysis of target mRNA expression was performed with real-time PCR using the relative standard curve method (Markó et al., 2016). TaqMan or SYBR green analysis was conducted according to the manufacturer's

instructions, using an Applied Biosystems 7500 Sequence Detector (Life Technologies Corporation, Carlsbad, CA, USA). The expression level of the target genes was normalized by the expression of 18S. Primers for were synthesized by Biotex (Berlin, Germany) and the sequences are as follows: K_V1.5 Forward sequence: 5'-GCTACTTCGATCCCTTGAGAAAT-3'; Reverse sequence: AGTAGTACAAAATGCCATCGAAGCT; 18S Forward sequence: 5'-ACATCCAAGGAAGGCAGCAG-3'; Reverse sequence 5'-TTTTCGTCACCTCCCG-3'.

Materials

All salts and other chemicals were obtained from Sigma-Aldrich (Germany) or Merck (Germany). All drugs were freshly dissolved on the day of each experiment according to the material sheet. The following concentrations of drugs were used: phenylephrine (Sigma-Aldrich) ranged from 0.01 to 100 μmol/L, 5-HT from 0.01 to 10 μM, DPO-1 (Tocris) 1 and 10 μmol/L, 100 nmol/L iberiotoxin (Sigma Aldrich). XE991 (Tocris) was applied at concentrations between 0.3 and 30 μM.

Statistics

Data represent mean ± SEM. EC₅₀ values were calculated using a Hill equation: $T = (B_0 - B_e)/(1 + ([D]/EC_{50})^n) + B_e$, where T is the tension in response to the drug (D); B_e is the maximum response induced by the drug; B₀ is a constant; EC₅₀ is the concentration of the drug that elicits a half-maximal response (Bychkov et al., 1998). Curve fittings were done by Prism 6 software using non-linear regression. Statistical significance was determined by two-way ANOVA or repeated-measures two-way ANOVA, followed by Bonferroni *post hoc* test, and using Prism 6 software. In case of unbalanced data, this software uses analysis of "unweighted means" to compare groups. Extra sum-of-squares F-test was performed for comparison of concentration-response curves and their 95% confidence intervals (CI). P-values < 0.05 were considered statistically significant. n represents the number of independent arteries tested or the number of cells measured. All rings were obtained from at least 3 different animals.

RESULTS

Regulation of Arterial Tone by DPO-1 Sensitive K_V1.5 Channels

First, we examined the role of K_V1.5 channels in the regulation of arterial tone by alpha1 adrenoceptor (alpha₁-AR) stimulation. In this set of experiments, we used the K_V1.5 channel blocker DPO-1 at concentrations assumed to be specific and potent for K_V1.5 channel inhibition (Stump et al., 2005; Lagrutta et al., 2006; Regan et al., 2006). In the presence of 1 μM DPO-1, mesenteric artery rings without PVAT [(-) PVAT] displayed similar contractions in response to phenylephrine (PE) compared to non-treated (-) PVAT control rings (Figures 1A,B). The 95% CI for EC₅₀ of control and DPO-1 treated rings were 1.21–1.79 μM and 0.78–1.40 μM, respectively. The anti-contractile effects of PVAT were also unchanged by 1 μM DPO-1: the 95% CI for EC₅₀ of control (+) PVAT and 1 μM DPO-1 (+) PVAT treated rings were 3.99–8.14 μM and 4.99–10.05 μM, respectively. To further confirm the results obtained with the K_V1.5 channel inhibitor,

we performed similar experiments using mesenteric artery rings from *Kcna5*^{-/-} mice. PE induced vasoconstrictions in (-) PVAT *Kcna5*^{-/-} rings were not different from those observed in (-) PVAT *Kcna5*^{+/+} rings (Figures 1C,D). Similarly, we observed PE induced vasoconstrictions in (+) PVAT *Kcna5*^{-/-} rings, which were not different from those observed in (+) PVAT *Kcna5*^{+/+} rings (Figures 1C,D). The 95% CI for EC₅₀ of (-) PVAT and (+) PVAT arteries isolated from *Kcna5*^{-/-} mice were 0.81–1.30 μM

and 4.94–7.79 μM, respectively. Data are summarized in Table 1. Experiments on rat mesenteric arteries showed similar results: Cumulative dose-response curves in response to serotonin (5-HT) were similar in vessel rings in the absence or presence of DPO-1 (Figure 1E). Together, the results suggest that K_v1.5 channels do not play a functionally relevant role in the control of arterial tone by PVAT, α₁-AR and 5-HT agonists, in both mouse and rat mesenteric arteries.

DPO-1 Sensitive K_v Channels Distinct from K_v1.5 May Regulate Arterial Tone

Next, we studied putative non-K_v1.5 channel dependent effects by using higher concentrations of DPO-1. Figure 2A shows that 1 μM DPO-1 had no effects on basal tone of *Kcna5*^{+/+} mesenteric artery rings with and without PVAT. Surprisingly, application of 10 μM DPO-1 resulted in a stable contraction of *Kcna5*^{+/+} mesenteric arteries without but not with PVAT (Figure 2B). This effect remained stable over 30 min and was observed also on rings isolated from *Kcna5*^{-/-} mice (Figure 2C). Thus, unexpectedly, inhibition of DPO-1 sensitive K_v channels distinct from K_v1.5 channels or other pathways could contribute to vascular tone in this preparation.

Effects of XE991 on K_v Currents, BK_{Ca} Currents and the Anti-Contractile Effects of PVAT

K_v currents were recorded in mesenteric artery VSMCs freshly isolated from *Kcna5*^{+/+} and *Kcna5*^{-/-} mice. We did not observe any difference between K_v current densities in *Kcna5*^{+/+} and *Kcna5*^{-/-} VSMCs. Moreover, K_v current inhibition by 30 μM XE991 was not different between *Kcna5*^{+/+} and *Kcna5*^{-/-} VSMCs (Figures 3A,B). 30 μM XE991 did not affect basal tone of mesenteric arteries prepared with or without PVAT (Figure S2).

In order to better understand the effects of XE991, we tested its actions on BK_{Ca} currents, potential mediators of the PVAT effect. VSMC *Kcna5*^{+/+} BK_{Ca} currents were recorded in the absence and presence of 30 μM XE991. 100 nM iberiotoxin (a potent and highly selective BK_{Ca} channel inhibitor) was used as positive control. While 30 μM XE991 did not affect the BK_{Ca} current, iberiotoxin almost completely inhibited the BK_{Ca} current. These results are consistent with plasma membrane VSMC BK_{Ca} channel activity resistant to XE991 *in situ*, at concentrations up to 30 μM of XE991 (Figures 3C,D).

Additionally, we tested the effects of 30 μM and 0.3 μM XE991 on the paracrine effects of PVAT on arterial tone. We found that XE991 even at the low concentration abolished the anti-contractile effects of PVAT. Interestingly, application of 0.3 and 30 μM XE991 resulted in a similar reduction of the anti-contractile effects of PVAT (Figures 4A,B). The EC₅₀ 95% CI values were 1.92–3.09 and 1.32–2.02 μM for (+) PVAT rings preincubated with 0.3 μM XE991 and 30 μM XE991, respectively; and 4.18–5.84 μM for (+) PVAT rings in the absence of XE991. (-) PVAT rings showed no difference, regardless of the absence or presence of 0.3 μM or 30 μM XE991. Data





TABLE 1 | EC₅₀ and its confidence intervals.

Condition	Mouse background	Without PVAT			With PVAT		
		EC ₅₀ μM	95% confidence interval (CI)	n	EC ₅₀ μM	95% confidence intervals (CI)	n
<i>Kcna5</i> ^{+/+}	129SVE-M	1.48	1.21–1.79	9	5.72	3.99–8.14	8
<i>Kcna5</i> ^{-/-}	129SVE-M	1.02	0.81–1.30	10	6.20	4.94–7.79	12
<i>Kcna5</i> ^{+/+} +1 μM DPO-1	129SVE-M	1.04	0.78–1.40	11	7.24	4.99–10.05	11
Control	C57BL/6	0.70	0.57–0.87	17	4.94	4.18–5.84	21
0.3 μM XE991	C57BL/6	0.48	0.30–0.75	5	2.43	1.92–3.09	13
30 μM XE991	C57BL/6	0.38	0.24–0.65	5	1.64	1.32–2.02	12

Data calculated from concentration-response curves to phenylephrine after normalization to maximum response from within each curve. For comparison of data and groups, see text and figures.




are presented in **Table 1**. Together, our data demonstrate that XE991 is a potent inhibitor of PVAT control of arterial tone at low concentrations similar to its potency of inhibiting K_v currents in VSMCs (Schleifenbaum et al., 2014). BK_{Ca} channels are however exempt from this inhibitory effect of XE991 (up to 30 μM).

DISCUSSION

Perivascular adipose tissue plays a potent anti-contractile role in the control of arterial tone along arterial segments of different vascular beds and species. The main findings of this study are threefold. First, XE991 inhibits the PVAT effect at nanomolar concentrations in mesenteric arteries of mice. Interestingly, similar concentrations were found in earlier studies to inhibit VSMC K_v currents (50% inhibition at 60 nM XE991) (Schleifenbaum et al., 2014). Second, *Kcna5*^{-/-} mice exhibited normal VSMC K_v currents and arterial contractions in the absence and presence of PVAT, whose effects were insensitive to DPO-1. Third, the KCNQ channel blocker XE991 does not affect plasma membrane VSMC BK_{Ca} channels at concentrations, which inhibit the anti-contractile effects of PVAT. Together, the results of our current study implicate KCNQ-type K_v channels in the XE991-mediated inhibition of the PVAT effects. Simultaneously, we exclude BK_{Ca} as well as K_v1.5 channels as potential downstream candidates in this process.

K_v1.5 in Regulation of Arterial Tone

In recent studies, K_v1.5 channels have been shown to determine microvascular tone and the arteriolar response to vasoconstrictors in rat cerebral arteries (Chen et al., 2006; Fancher et al., 2015). Furthermore, K_v1.5 channels in the heart are essential in coupling myocardial blood flow to cardiac metabolism (Ohanyan et al., 2015). Moreover, hypertension is associated with altered expression of vascular K_v1.5 channels (Wang et al., 1997; Platoshyn et al., 2001; Cox and Rusch, 2002; Cox et al., 2008; Cidat et al., 2014). Therefore, K_v1.5 channels may represent interesting putative targets of PVAT and that raised the question of their potential involvement in the regulation of arterial tone by phenylephrine in mouse mesenteric arteries. Our results suggest that K_v1.5 channels are however not involved. In effect, the anti-contractile effects of PVAT were not different between *Kcna5*^{-/-} and *Kcna5*^{+/+} arteries. Additionally, the K_v1.5 channel inhibitor DPO-1 at 1 μM displayed no effect on vasoconstrictions in the absence and presence of PVAT. Notably, the mechanism of DPO-1 action (“open channel” blocker) might be a potential confounding factor, since K_v1.5 channels are activated at V_{0.5} of -14 mV (Grissmer et al., 1994). However, the genetic approach had the




advantage to study vascular effects in the absence of K_V1.5 channels avoiding possible confounders related to membrane potential-dependent drug mechanisms. Furthermore, we did not observe any significant differences in the K_V current density and inhibition by XE991 in *Kcna5*^{-/-} and *Kcna5*^{+/+} VSMCs. Therefore, we conclude that K_V1.5 channels have no apparent role in PVAT-dependent relaxation and are not the XE991 sensitive channels that contribute to this process. This conclusion is in line with our previous results obtained on cloned and heterologously expressed K_V1.5 alpha subunits in HEK293 cells (Schleifenbaum et al., 2014). In these experiments, 100 nM XE991 failed to block K_V1.5 currents. We also observed similar responses of arterial rings without PVAT to PE and 5-HT, regardless of genetic deletion of K_V1.5 alpha subunits or pharmacological blockade of K_V1.5 channels by DPO-1. To our knowledge, this is the first study to firmly establish that K_V1.5 channels are not involved in the regulation of arterial tone of systemic visceral arteries of mice and rats, at least in mesenteric

arteries. Our conclusions substantiate the work of other groups, namely that patients with genetic mutations of *KCNA5* exhibit pulmonary arterial hypertension and arterial fibrillation but not systemic hypertension (Yang et al., 2009; Wipff et al., 2010; Machado et al., 2015). Together, our data questions the contribution of K_V1.5 channels in a number of small resistance arteries to peripheral arterial resistance. The findings are however not generalizable to all vascular beds as K_V1.5 channels were demonstrated to play important vasoregulatory functions in cerebral arteries and in *Gracilis* skeletal muscle arteries (Chen et al., 2006; Fanher et al., 2015).

DPO-1 Sensitive K⁺ Channels and Pathways Distinct from K_V1.5 Involved in Regulation of Arterial Tone

DPO-1 was described as a specific K_V1.5 inhibitor at micromolar concentrations (Stump et al., 2005; Lagrutta et al., 2006; Regan et al., 2006). It exerts its inhibitory effects through binding



with several key residues in the S5- pore loop-S6 domains, thus resulting in blockade of the open state of the K_v1.5 channel (Karczewski et al., 2009; Du et al., 2010). Other studies have suggested a DPO-1 preference for vascular K_v1.5 channels, though with limited selectivity (Fancher et al., 2015). In this study, DPO-1 (1–10 μM) inhibited the outward K⁺ current in arterial smooth muscle cells from wild-type (*Kcna5*^{+/+}) mice and mice lacking the *Kcna5* gene; however, the inhibitory effect was much greater in cells from *Kcna5*^{+/+} mice (Fancher et al., 2015). Subsequently, our data in Figure 2 suggests that 10 μM DPO-1 induces contractions by inhibiting channels distinct from K_v1.5 channels. Those channels appear to be important for the regulation of resting arterial tone. Interestingly, DPO-1 is able to block K_v1.3 channel currents at EC₅₀ of 3.1 μM in human T cells (Zhao et al., 2013). *Kcna3* mRNA expression is also observed in mouse mesenteric arteries (Fountain et al., 2004; Cidad et al., 2014). Although the ability of K_v1.5 and K_v1.3 to form heteromers (Kv1.5/Kv1.3) (Villalonga et al., 2007) impede the study of their specific roles in native tissues *in vivo*, it is

intriguing to speculate that K_v1.3 channels could represent a putative target of PVAT regulation of arterial tone. Future studies are necessary to clarify their role.

Effects of XE991 on K_v channels, BK_{Ca} Channels and Paracrine PVAT Effects

In the mouse mesenteric arteries, *Kcnq1*, *Kcnq4*, and *Kcnq5* expression was demonstrated at the mRNA level (Yeung et al., 2007), whereas mRNA expression of *Kcnq2*, *Kcnq3* was not detectable or only at borderline low levels (Yeung et al., 2007; Schleifenbaum et al., 2014). We previously suggested that KCNQ type K_v channels are key players in the paracrine role for perivascular adipose tissue in the regulation of arterial tone (Schleifenbaum et al., 2010; Zavaritskaya et al., 2013); based on mRNA expression levels (see above), KCNQ1, KCNQ4, and/or KCNQ5 channels are likely candidates. This suggestion is also based on the ability of 30 μM XE991 (pan KCNQ blocker) and 2 mmol/L 4-aminopyridine (pan K_v blocker) to block the anti-contractile effects of PVAT. Interestingly, KCNQ channel opens normalized reduced anti-contractile effects of PVAT in a rat model of hypertension (Zavaritskaya et al., 2013), which suggests therapeutic perspectives of KCNQ targeting in cardiovascular disease. It is thus imperative to better understand the actions of these compounds on the vasculature. In order to obtain more information about the potency of XE991 inhibition on PVAT-mediated anti-contractility, we performed experiments with a 100x lower concentration of XE991. The data show that this considerably reduced concentration still exerted an inhibitory impact on PVAT regulation of arterial tone (Figures 4A,B), while basal tone was unaffected in rings (+) or (–) PVAT (Figure S2). The incomplete inhibition observed, however suggests the possible involvement of additional K⁺ channels in this process. Furthermore, our data demonstrates that VSMC plasma membrane BK_{Ca} channels are not involved in the effects of XE991 on PVAT regulation, since XE991 does not inhibit BK_{Ca} currents (this study). This is in line with our previous findings indicating that the paracrine effects of PVAT on arterial tone are normal in the presence of BK_{Ca} channel blockers or in arteries that lack BK_{Ca} beta1 channel subunits (Fésüs et al., 2007; Zavaritskaya et al., 2013).

Previous studies examined the ability of XE991 to inhibit heterologously expressed K_v1.5 alpha subunits. We found that 100 nM and 30 μM XE991 was unable to block monomeric K_v1.5 channels heterologously expressed in HEK293 or CHO cells (Zavaritskaya et al., 2013; Schleifenbaum et al., 2014). Interestingly, Zhong et al. found a small (~20% at (+) 5 mV) inhibiting effect for 10 μM XE991 on heterologously expressed heterotetrameric K_v1.2/K_v1.5 and K_v2.1/K_v9.3 channel subunits (Zhong et al., 2010). The block of K_v1.2/K_v1.5 channels was voltage dependent, and evident only at voltages positive to -15 mV. Our present study contributes to the debate about the importance of accessory subunits for determining the pharmacological properties of vascular K⁺ channels *in vivo*. Since regulatory K_vbeta1.3 subunits can decrease the sensitivity of K_v1.5 channels to pharmacological inhibitors such as DPO-1 (Gonzalez et al., 2002; Arias et al.,

2007; Du et al., 2010), one could argue that DPO-1 is not a reliable tool to study K_v1.5 channels in native tissues. However, we believe that our pharmacological approach in combination with the *Kcna5*^{-/-} mouse model firmly demonstrates that the XE991 sensitive regulation of arterial tone by PVAT regulation does not involve native vascular K_v1.5 channels.

CONCLUSION

In conclusion, our results demonstrate that K_v1.5 channels are not involved in the control of mesenteric arterial tone and its regulation by PVAT in mouse and rat mesenteric arteries. The nature of the 10 μM DPO-1 sensitive component is unclear, but is most likely related to non-specificity of this drug, for example in targeting vascular K_v1.3 and/or KCNQ channels *in situ*. Importantly, the inhibitory effects of XE991 on PVAT vasorelaxation are rather related to inhibition of KCNQ-type K_v channels than BK_{Ca} channels. These data unequivocally substantiate the hypothesis of different targets of perivascular relaxing factor(s), which employ distinct mechanisms to mediate an anti-contractile effect. Further studies should focus on the enhancement of these relaxing factors, as these will be beneficial for patients with cardiovascular diseases.

REFERENCES

- Arias, C., Guizy, M., David, M., Marzian, S., González, T., Decher, N., et al. (2007). Kvβ1.3 reduces the degree of stereoselective bupivacaine block of Kv1.5 channels. *Anesthesiology* 107, 641–651. doi: 10.1097/01.anes.0000282100.32923.5c
- Bentzen, B. H., Olesen, S. P., Ronn, L. C. B., and Grunnet, M. (2014). BK channel activators and their therapeutic perspectives. *Front. Physiol.* 5:389. doi: 10.3389/fphys.2014.00389
- Bychkov, R., Gollasch, M., Steinke, T., Ried, C., Luft, F. C., and Haller, H. (1998). Calcium-activated potassium channels and nitrate-induced vasodilation in human coronary arteries. *J. Pharmacol. Exp. Ther.* 285, 293–298.
- Chen, T. T., Luykenaar, K. D., Walsh, E. J., Walsh, M. P., and Cole, W. C. (2006). Key role of Kv1 channels in vasoregulation. *Circ. Res.* 99, 53–60. doi: 10.1161/01.RES.0000229654.45090.57
- Cidad, P., Novensà, L., Garabito, M., Batlle, M., Dantas, A. P., Heras, M., et al. (2014). K(+) channels expression in hypertension after arterial injury, and effect of selective Kv1.3 blockade with PAP-1 on intimal hyperplasia formation. *Cardiovasc. Drugs Ther.* 28, 501–511. doi: 10.1007/s10557-014-6554-5
- Cox, R. H., Fromme, S. J., Folander, K. L., and Swanson, R. J. (2008). Voltage gated K(+) channel expression in arteries of Wistar-Kyoto and spontaneously hypertensive rats. *Am. J. Hypertens.* 21, 213–218. doi: 10.1038/ajh.2007.44
- Cox, R. H., and Rusch, N. J. (2002). New expression profiles of voltage-gated ion channels in arteries exposed to high blood pressure. *Microcirculation* 9, 243–257. doi: 10.1038/sj.mn.7800140
- Du, Y., Zhang, X., Tu, D., Zhao, N., Liu, Y., Xiao, H., et al. (2010). Molecular determinants of Kv1.5 channel block by diphenyl phosphine oxide-1. *J. Mol. Cell. Cardiol.* 48, 1111–1120. doi: 10.1016/j.yjmcc.2010.02.010
- Elmedyby, P., Calloe, K., Schmitt, N., Hansen, R. S., Grunnet, M., and Olesen, S.-P. (2007). Modulation of ERG channels by XE991. *Basic Clin. Pharmacol. Toxicol.* 100, 316–322. doi: 10.1111/j.1742-7843.2007.00048.x
- Essin, K., Welling, A., Hofmann, F., Luft, F. C., Gollasch, M., and Moosmang, S. (2007). Indirect coupling between Cav1.2 channels and ryanodine receptors to

AUTHOR CONTRIBUTIONS

All authors planned and designed the experimental studies. DT and NW performed the wire myography experiments. MK and JT performed the electrophysiological experiments. DT and MG drafted the article, and all authors contributed to its completion.

FUNDING

This study was supported by grants from the Deutsche Forschungsgemeinschaft (DFG) to MG and the Deutsche Akademische Austauschdienst (DAAD) to MG and DT. DT is recipient of ERA/EDTA and DAAD fellowships and JT is an Alexander von Humboldt fellow.

ACKNOWLEDGMENTS

We thank Dr. Helmut Kettenmann (MDC Berlin) for providing *Kcna5*^{-/-} mice and Dr. Lajos Markó for helping with RT-qPCR.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <http://journal.frontiersin.org/article/10.3389/fphys.2016.00335>

- generate Ca²⁺ sparks in murine arterial smooth muscle cells. *J. Physiol.* 584, 205–219. doi: 10.1113/jphysiol.2007.138982
- Fancher, I. S., Butcher, J. T., Brooks, S. D., Rottgen, T. S., Skaff, P. R., Frisbee, J. C., et al. (2015). Diphenyl phosphine oxide-1-sensitive K⁺ channels contribute to the vascular tone and reactivity of resistance arteries from brain and skeletal muscle. *Microcirculation* 22, 315–325. doi: 10.1111/micc.12201
- Fésüs, G., Dubrovska, G., Gorzelnik, K., Kluge, R., Huang, Y., Luft, F. C., et al. (2007). Adiponectin is a novel humoral vasodilator. *Cardiovasc. Res.* 75, 719–727. doi: 10.1016/j.cardiores.2007.05.025
- Fountain, S. J., Cheong, A., Flemming, R., Mair, L., Sivaprasadarao, A., and Beech, D. J. (2004). Functional up-regulation of KCNA gene family expression in murine mesenteric resistance artery smooth muscle. *J. Physiol.* 556, 29–42. doi: 10.1113/jphysiol.2003.058594
- Gao, Y.-J., Zeng, Z., Teoh, K., Sharma, A. M., Abouzahr, L., Cybulsky, I., et al. (2005). Perivascular adipose tissue modulates vascular function in the human internal thoracic artery. *J. Thorac. Cardiovasc. Surg.* 130, 1130–1136. doi: 10.1016/j.jtcvs.2005.05.028
- Gollasch, M., Ried, C., Bychkov, R., Luft, F. C., and Haller, H. (1996). K⁺ currents in human coronary artery vascular smooth muscle cells. *Circ. Res.* 78, 676–688. doi: 10.1161/01.RES.78.4.676
- Gollasch, M., Wellman, G. C., Knot, H. J., Jaggar, J. H., Damon, D. H., Bonev, A. D., et al. (1998). Ontogeny of local sarcoplasmic reticulum Ca²⁺ signals in cerebral arteries: Ca²⁺ sparks as elementary physiological events. *Circ. Res.* 83, 1104–1114.
- Gonzalez, T., Navarro-Polanco, R., Arias, C., Caballero, R., Moreno, I., Delpon, E., et al. (2002). Assembly with the Kvβ1.3 subunit modulates drug block of hKv1.5 channels. *Mol. Pharmacol.* 62, 1456–1463. doi: 10.1124/mol.62.6.1456
- Grissmer, S., Nguyen, A. N., Aiyar, J., Hanson, D. C., Mather, R. J., Gutman, G. A., et al. (1994). Pharmacological characterization of five cloned voltage-gated K⁺ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. *Mol. Pharmacol.* 45, 1227–1234.

- Karczewski, J., Kiss, L., Kane, S. A., Koblan, K. S., Lynch, R. J., and Spencer, R. H. (2009). High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5. *Biochem. Pharmacol.* 77, 177–185. doi: 10.1016/j.bcp.2008.09.035
- Khanamiri, S., Soltysinska, E., Jepps, T. A., Bentzen, B. H., Chadha, P. S., Schmitt, N., et al. (2013). Contribution of Kv7 channels to basal coronary flow and active response to ischemia. *Hypertension* 62, 1090–1097. doi: 10.1161/HYPERTENSIONAHA.113.01244
- Lagrutta, A., Wang, J., Fermini, B., and Salata, J. J. (2006). Novel, potent inhibitors of human Kv1.5 K⁺ channels and ultrarapidly activating delayed rectifier potassium current. *J. Pharmacol. Exp. Ther.* 317, 1054–1063. doi: 10.1124/jpet.106.101162
- Lee, R. M. K. W., Bader, M., Alenina, N., Santos, R. A. S., Gao, Y.-J., and Lu, C. (2011). Mas receptors in modulating relaxation induced by perivascular adipose tissue. *Life Sci.* 89, 467–472. doi: 10.1016/j.lfs.2011.07.016
- Lee, Y.-C., Chang, H.-H., Chiang, C.-L., Liu, C.-H., Yeh, J.-I., Chen, M.-F., et al. (2011). Role of perivascular adipose tissue-derived methyl palmitate in vascular tone regulation and pathogenesis of hypertension. *Circulation* 124, 1160–1171. doi: 10.1161/CIRCULATIONAHA.111.027375
- Lohn, M., Dubrovskaya, G., Lauterbach, B., Luft, F. C., Gollasch, M., and Sharma, A. M. (2002). Periadventitial fat releases a vascular relaxing factor. *FASEB J.* 16, 1057–1063. doi: 10.1096/fj.02-0024com
- Lynch, F. M., Withers, S. B., Yao, Z., Werner, M. E., Edwards, G., Weston, A. H., et al. (2013). Perivascular adipose tissue-derived adiponectin activates BK(Ca) channels to induce anticontractile responses. *Am. J. Physiol. Heart. Circ. Physiol.* 304, H786–H795. doi: 10.1152/ajpheart.00697.2012
- Machado, R. D., Southgate, L., Eichstaedt, C. A., Aldred, M. A., Austin, E. D., Best, D. H., et al. (2015). Pulmonary arterial hypertension: a current perspective on established and emerging molecular genetic defects. *Hum. Mutat.* 36, 1113–1127. doi: 10.1002/humu.22904
- Markó, L., Vigolo, E., Hinze, C., Park, J.-K., Roël, G., Balogh, A., et al. (2016). Tubular epithelial NF- κ B activity regulates ischemic AKI. *J. Am. Soc. Nephrol.* doi: 10.1681/ASN.2015070748. [Epub ahead of print].
- Nelson, M. T., and Quayle, J. M. (1995). Physiological roles and properties of potassium channels in arterial smooth muscle. *Am. J. Physiol.* 268, C799–C822.
- Ohanyan, V., Yin, L., Bardakjian, R., Kolz, C., Enrick, M., Hakobyan, T., et al. (2015). Requisite role of Kv1.5 channels in coronary metabolic dilation. *Circ. Res.* 117, 612–621. doi: 10.1161/CIRCRESAHA.115.306642
- Pannasch, U., Färber, K., Nolte, C., Blonski, M., Yan Chiu, S., Messing, A., et al. (2006). The potassium channels Kv1.5 and Kv1.3 modulate distinct functions of microglia. *Mol. Cell. Neurosci.* 33, 401–411. doi: 10.1016/j.mcn.2006.08.009
- Park, S. W., Noh, H. J., Sung, D. J., Kim, J. G., Kim, J. M., Ryu, S.-Y., et al. (2015). Hydrogen peroxide induces vasorelaxation by enhancing 4-aminopyridine-sensitive Kv currents through S-glutathionylation. *Pflügers Arch. Eur. J. Physiol.* 467, 285–297. doi: 10.1007/s00424-014-1513-3
- Platoshyn, O., Yu, Y., Golovina, V. A., McDaniel, S. S., Krick, S., Li, L., et al. (2001). Chronic hypoxia decreases K(V) channel expression and function in pulmonary artery myocytes. *Am. J. Physiol. Lung. Cell Mol. Physiol.* 280, L801–L812.
- Plüger, S., Faulhaber, J., Fürstenau, M., Löhn, M., Waldschütz, R., Gollasch, M., et al. (2000). Mice with disrupted BK channel beta1 subunit gene feature abnormal Ca(2+) spark/STOC coupling and elevated blood pressure. *Circ. Res.* 87, E53–60. doi: 10.1161/01.RES.87.11.e53
- Regan, C. P., Wallace, A. A., Cresswell, H. K., Atkins, C. L., and Lynch, Jr., J. J. (2006). *In vivo* cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker, (2-Isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate. *J. Pharmacol. Exp. Ther.* 316, 727–732. doi: 10.1124/jpet.105.092197
- Schleifenbaum, J., Kassmann, M., Szijártó, I. A., Hercule, H. C., Tano, J.-Y., Weinert, S., et al. (2014). Stretch-activation of angiotensin II type 1a receptors contributes to the myogenic response of mouse mesenteric and renal arteries. *Circ. Res.* 115, 263–272. doi: 10.1161/CIRCRESAHA.115.302882
- Schleifenbaum, J., Köhn, C., Voblova, N., Dubrovskaya, G., Zavarirskaya, O., Gloe, T., et al. (2010). Systemic peripheral artery relaxation by KCNQ channel openers and hydrogen sulfide. *J. Hypertens.* 28, 1875–1882. doi: 10.1097/HJH.0b013e32833c20d5
- Schroeder, B. C., Hechenberger, M., Weinreich, F., Kubisch, C., and Jentsch, T. J. (2000). KCNQ5, a novel potassium channel broadly expressed in brain, mediates m-type currents. *J. Biol. Chem.* 275, 24089–24095. doi: 10.1074/jbc.M003245200
- Sobey, C. G. (2001). Potassium channel function in vascular disease. *Arterioscler. Thromb. Vasc. Biol.* 21, 28–38. doi: 10.1161/01.ATV.21.1.28
- Søgaard, R., Ljungström, T., Pedersen, K. A., Olesen, S. P., and Jensen, B. S. (2001). KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology. *Am. J. Physiol. Cell Physiol.* 280, C859–C866.
- Stott, J. B., Barrese, V., Jepps, T. A., Leighton, E. V., and Greenwood, I. A. (2015). Contribution of Kv7 channels to natriuretic peptide mediated vasodilation in normal and hypertensive rats. *Hypertension* 65, 676–682. doi: 10.1161/HYPERTENSIONAHA.114.04373
- Stump, G. L., Wallace, A. A., Regan, C. P., and Lynch, J. J. (2005). *In vivo* antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. *J. Pharmacol. Exp. Ther.* 315, 1362–1367. doi: 10.1124/jpet.105.092197
- Tanaka, Y., Tang, G., Takizawa, K., Otsuka, K., Eghbali, M., Song, M., et al. (2006). Kv channels contribute to nitric oxide- and atrial natriuretic peptide-induced relaxation of a rat conduit artery. *J. Pharmacol. Exp. Ther.* 317, 341–354. doi: 10.1124/jpet.105.096115
- Tano, J.-Y., and Gollasch, M. (2014). Calcium-activated potassium channels in ischemia reperfusion: a brief update. *Front. Physiol.* 5:381. doi: 10.3389/fphys.2014.00381
- Tano, J. Y., Schleifenbaum, J., and Gollasch, M. (2014). Perivascular adipose tissue, potassium channels, and vascular dysfunction. *Arterioscler. Thromb. Vasc. Biol.* 34, 1827–1830. doi: 10.1161/ATVBAHA.114.303032
- Verlohren, S., Dubrovskaya, G., Tsang, S. Y., Essin, K., Luft, F. C., Huang, Y., et al. (2004). Visceral periaortic adipose tissue regulates arterial tone of mesenteric arteries. *Hypertension* 44, 271–276. doi: 10.1161/01.HYP.0000140058.28994.ec
- Villalonga, N., Escalada, A., Vicente, R., Sánchez-Tilló, E., Celada, A., Solsona, C., et al. (2007). Kv1.3/Kv1.5 heteromeric channels compromise pharmacological responses in macrophages. *Biochem. Biophys. Res. Commun.* 352, 913–918. doi: 10.1016/j.bbrc.2006.11.120
- Wang, H. S., Brown, B. S., McKinnon, D., and Cohen, I. S. (2000). Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991. *Mol. Pharmacol.* 57, 1218–1223.
- Wang, H. S., Pan, Z., Shi, W., Brown, B. S., Wymore, R. S., Cohen, I. S., et al. (1998). KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. *Science* 282, 1890–1893. doi: 10.1126/science.282.5395.1890
- Wang, J., Juhaszova, M., Rubin, L. J., and Yuan, X. J. (1997). Hypoxia inhibits gene expression of voltage-gated K⁺ channel alpha subunits in pulmonary artery smooth muscle cells. *J. Clin. Invest.* 100, 2347–2353. doi: 10.1172/JCI119774
- Weston, A. H., Egner, I., Dong, Y., Porter, E. L., Heagerty, A. M., and Edwards, G. (2013). Stimulated release of a hyperpolarizing factor (ADHF) from mesenteric artery perivascular adipose tissue: involvement of myocyte BKCa channels and adiponectin. *Br. J. Pharmacol.* 169, 1500–1509. doi: 10.1111/bph.12157
- Wipf, J., Dieudé, P., Guedj, M., Ruiz, B., Riemekasten, G., Cracowski, J. L., et al. (2010). Association of a KCNA5 gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population. *Arthritis Rheum.* 62, 3093–3100. doi: 10.1002/art.27607
- Yang, Y., Li, J., Lin, X., Yang, Y., Hong, K., Wang, L., et al. (2009). Novel KCNA5 loss-of-function mutations responsible for atrial fibrillation. *J. Hum. Genet.* 54, 277–283. doi: 10.1038/jhg.2009.26
- Yeung, S. Y. M., and Greenwood, I. A. (2005). Electrophysiological and functional effects of the KCNQ channel blocker XE991 on murine portal vein smooth muscle cells. *Br. J. Pharmacol.* 146, 585–595. doi: 10.1038/sj.bjp.0706342

- Yeung, S. Y. M., Pucovski, V., Moffatt, J. D., Saldanha, L., Schwake, M., Ohya, S., et al. (2007). Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. *Br. J. Pharmacol.* 151, 758–770. doi: 10.1038/sj.bjp.0707284
- Zavaritskaya, O., Zhuravleva, N., Schleifenbaum, J., Gloe, T., Devermann, L., Kluge, R., et al. (2013). Role of KCNQ channels in skeletal muscle arteries and periadventitial vascular dysfunction. *Hypertension* 61, 151–159. doi: 10.1161/HYPERTENSIONAHA.112.197566
- Zhao, N., Dong, Q., Du, L.-L., Fu, X.-X., Du, Y.-M., and Liao, Y.-H. (2013). Potent suppression of Kv1.3 potassium channel and IL-2 secretion by diphenyl phosphine oxide-1 in human T cells. *PLoS ONE* 8:e64629. doi: 10.1371/journal.pone.0064629
- Zhong, X. Z., Harhun, M. I., Olesen, S. P., Ohya, S., Moffatt, J. D., Cole, W. C., et al. (2010). Participation of KCNQ (Kv7) potassium channels in myogenic control of cerebral arterial diameter. *J. Physiol.* 588, 3277–3293. doi: 10.1113/jphysiol.2010.192823

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Tsvetkov, Tano, Kassmann, Wang, Schubert and Gollasch. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.